Previous 10 | Next 10 |
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare...
ADMA Biologics (ADMA) has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock.Record date for such dividend distribution is Dec. 30, 2020 and the rights plan expires on Dec. 15, 2021. ...
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors h...
4 Penny Stocks To Watch Today Throughout the month, penny stocks continue to gain steam. Whether it’s micro-caps or small cap stocks , the focus is on making quick profits. One of the top sectors to watch has been biotech. Now, I know what you might be thinking, it’...
ADMA Biologics ([[ADMA]] +5.3%) amended its existing senior secured term loan with Perceptive Advisors providing an additional loan tranche of $15M raising the total size of the credit facility to $100M.Also, the facility will provide a two-year extension of the interest only period thro...
Increases S ize of Facility and E xtends I nterest- O nly P eriod E nabling ADMA to R each P rofitability P rior to M aturity ...
RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Dec. 01, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, t...
FinancialBuzz.com News Commentary New York, NY (11/23/2020) – Biotechnology and pharmaceutical companies are now very close to an effective vaccine to fight the current pandemic. Earlier this month, Pfizer and BioNTech SE announced that their vaccine candidate was found to be mor...
ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 headwinds. Unfortunately, the healthcare sector is experiencing some selling pressure after the...
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...